Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) EBITDA (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed EBITDA for 4 consecutive years, with -$2.1 million as the latest value for Q4 2020.

  • Quarterly EBITDA fell 76.36% to -$2.1 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$6.3 million through Dec 2020, down 48.85% year-over-year, with the annual reading at -$15.6 million for FY2024, 85.94% down from the prior year.
  • EBITDA hit -$2.1 million in Q4 2020 for Monopar Therapeutics, down from -$1.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$373839.0 in Q1 2017 to a low of -$14.9 million in Q3 2017.
  • Historically, EBITDA has averaged -$1.9 million across 4 years, with a median of -$897552.5 in 2018.
  • Biggest YoY gain for EBITDA was 95.69% in 2018; the steepest drop was 134.42% in 2018.
  • Year by year, EBITDA stood at -$713583.0 in 2017, then decreased by 24.79% to -$890472.0 in 2018, then crashed by 35.39% to -$1.2 million in 2019, then plummeted by 76.36% to -$2.1 million in 2020.
  • Business Quant data shows EBITDA for MNPR at -$2.1 million in Q4 2020, -$1.6 million in Q3 2020, and -$1.4 million in Q2 2020.